siRNA conjugate and preparation method thereof
Provided are an siRNA-polymer conjugate, and a method for preparing the same, and more specifically, to a hybrid conjugate formed by covalently bonding siRNA and a polymeric compound for improving the in vivo stability of siRNA, and to a preparation method of the hybrid conjugate. The conjugate of the present invention can improve the in vivo stability of siRNA, thereby achieving an efficient delivery of therapeutic siRNA into cells and exhibiting the activity of siRNA even with a small dose of a relative low concentration. Therefore, the conjugate can advantageously be used as not only an siRNA treatment tool for cancers and other infectious disease, but also a novel type siRNA delivery system.
1. An siRNA-polymer compound conjugate of the following structure:
A-X-R-Y-B
where, one of A and B is a hydrophilic polymer compound and the other is a hydrophobic compound; X and Y are independently a simple covalent bond or a linker-mediated covalent bond; and R is siRNA,
wherein the hydrophobic compound is C 16 ˜C 50 hydrocarbon or cholesterol which has a molecular weight of 250 to 1,000.
2. The conjugate of claim 1 , wherein the hydrophilic polymer compound and the hydrophobic compound are conjugated to the same strand of siRNA.
3. The conjugate of claim 1 , wherein the hydrophilic polymer compound and the hydrophobic compound are conjugated to both strands of siRNA.
4. The conjugate of claim 1 , wherein a single strand of the siRNA (R) comprises 19 to 31 nucleotides.
5. The conjugate of claim 1 , wherein the covalent bond (X, Y) is a non-degradable bond or a degradable bond.
6. The conjugate of claim 5 , wherein the non-degradable bond is an amide bond or a phosphate bond.
7. The conjugate of claim 5 , wherein the degradable bond is selected from a disulfide bond, an acid-cleavable bond, an ester bond, an anhydride bond, a biodegradable bond and an enzyme-cleavable bond.
8. The conjugate of claim 1 , wherein the hydrophilic polymer compound is a non-ionic polymer compound having a molecular weight of 1,000 to 10,000.
9. The conjugate of claim 8 , wherein the hydrophilic polymer compound is selected from a group consisting of polyethylene glycol (PEG), polyvinylpyrolidone, and polyoxazoline.
10. A nanoparticle consisting of siRNA conjugates of claim 1 .
11. A pharmaceutical composition comprising a pharmaceutically effective amount of an siRNA-polymer compound conjugate of claim 1 .
12. A pharmaceutical composition comprising a pharmaceutically effective amount of the nanoparticles of claim 10 .